Please use this identifier to cite or link to this item: https://doi.org/10.21873/invivo.11835
Title: Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience
Authors: Meng, Katherine 
Lim, Keith 
Lee, Chia Ching
Chia, David
Ooi, Kiat Huat 
Soon, Yu Yang 
Tey, Jeremy 
Keywords: Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
Prostate cancer
radiotherapy
toxicity
proctitis
dose escalation
androgen deprivation therapy
ANDROGEN DEPRIVATION THERAPY
INTENSITY-MODULATED RADIOTHERAPY
CONFORMAL RADIATION-THERAPY
CARDIOVASCULAR MORTALITY
RADICAL PROSTATECTOMY
BIOCHEMICAL FAILURE
RTOG
RISK
SUPPRESSION
IMPACT
Issue Date: 1-Mar-2020
Publisher: INT INST ANTICANCER RESEARCH
Citation: Meng, Katherine, Lim, Keith, Lee, Chia Ching, Chia, David, Ooi, Kiat Huat, Soon, Yu Yang, Tey, Jeremy (2020-03-01). Clinical Outcomes of Dose-escalated Radiotherapy for Localised Prostate Cancer: A Single-institution Experience. IN VIVO 34 (2) : 757-765. ScholarBank@NUS Repository. https://doi.org/10.21873/invivo.11835
Abstract: © 2020 International Institute of Anticancer Research. All rights reserved. Background/Aim: To report the outcomes of patients with prostate cancer treated with dose-escalated radiotherapy over a 15-year period at our Institution. Patients and Methods: Patients with biopsy-proven cT1-4N0M0 disease who received radical external beam radiotherapy (EBRT) were reviewed. The endpoints were 5-year overall survival (OS), freedom from biochemical failure (FFBF) and late treatment toxicities. Results: A total of 236 patients were eligible. Median follow-up was 70 months. Low-, intermediate- and high-risk disease was found in 9%; 29% and 62% of patients, respectively. The median radiation dose was 73.8 Gy. Overall 42% of patients had dose escalation to >74 Gy. Five-year OS and FFBF were 95.2%/81.6%/75.4% and 95.0%/98.0%/82.0% for low- /intermediate-/high-risk patients, respectively. Dose escalation to >74 Gy did not improve FFBF (hazard ratio=0.97, 95% confidence intervaI=0.43-2.19, p=0.93) and was associated with a 4.3-fold increase in the odds of grade 3 or more rectal bleeding (p<0.01). Conclusion: Dose escalation to >74 Gy did not improve OS or FFBF but was associated with a higher rate of grade 3 or more rectal haemorrhage.
Source Title: IN VIVO
URI: https://scholarbank.nus.edu.sg/handle/10635/183426
ISSN: 0258851X
17917549
DOI: 10.21873/invivo.11835
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Prostate paper.pdfPublished version209.97 kBAdobe PDF

OPEN

PublishedView/Download

Page view(s)

48
checked on Jan 21, 2021

Download(s)

2
checked on Jan 21, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.